Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The pharma industry – and clinical trials in particular – have been significantly disrupted by the Covid-19 pandemic.
For example, lockdowns and social distancing have made it all but impossible for many ill patients to visit their trial sites for monitoring and medication.
It has also been challenging for the industry to retain communication channels with healthcare professionals (HCPs) and patients, both during trials and commercialisation of products.
Issues with the stability of global supply chains has further complicated the industry’s ability to continue its clinical trials and selling its product on the market.